Clinical Trial Update: Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial update for olokizumab in moderately to severely active rheumatoid arthritis; results posted indicating efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Olokizumab (olokizumab)

Snippet

Sponsor: R-Pharm International, LLC | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2022-06-07